Lipocine (NASDAQ:LPCN) Stock Passes Below 200-Day Moving Average – Here’s What Happened

Lipocine Inc. (NASDAQ:LPCN)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.60 and traded as low as $5.13. Lipocine shares last traded at $5.48, with a volume of 33,584 shares changing hands.

Analysts Set New Price Targets

LPCN has been the subject of a number of analyst reports. StockNews.com upgraded shares of Lipocine from a “hold” rating to a “buy” rating in a research report on Monday, October 14th. Alliance Global Partners started coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Down 0.5 %

The stock has a fifty day moving average of $4.39 and a two-hundred day moving average of $5.60. The stock has a market cap of $29.28 million, a price-to-earnings ratio of -3.20 and a beta of 1.22.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The firm had revenue of $0.09 million for the quarter. On average, research analysts expect that Lipocine Inc. will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC boosted its position in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the period. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.